Human ESC/iPSC-based "Omics" and Bioinformatics for Translational Research. Drug Discov Today Dis Models 2012;9(4):e161-e170
Date
01/01/2012Pubmed ID
23682293Pubmed Central ID
PMC3653319DOI
10.1016/j.ddmod.2012.02.003Scopus ID
2-s2.0-84876690042 (requires institutional sign-in at Scopus site) 7 CitationsAbstract
The establishment of human embryonic stem cell lines (hESCs) created the basis for new approaches in regenerative medicine and drug discovery. Despite the potential of hESCs for cell based therapies, ethical controversies limit their use. These obstacles could be overcome by induced pluripotent stem cells (iPSCs) that are generated by reprogramming somatic cells. Before iPSCs can be used for clinical applications, however, they must be thoroughly analyzed for aberrations in the genome, epigenome, transcriptome, and proteome. Here, we review how 'omics' technologies can be employed for a quantitative and definitive assessment of these cells.